BIOPHARMA SOLUTIONS

Helping bring new cancer therapies to patients sooner

Guardant Health is proud to partner with over 150 biopharma companies to support their efforts in bringing the next generation of cancer therapeutics to patients sooner. Our scientists are pioneering multiomic approaches to power precision oncology with deeper insights. Our portfolio of innovative solutions and best-in-class services span translational research, clinical development and commercialization, and real-world evidence.

Contact Us
Epigenomics for oncology Translational research Clinical development & commercialization Real-world evidence

Harnessing the power of epigenomics for precision oncology

Epigenetic changes have a tremendous impact on cancer development and progression, yet epigenomic biomarkers remain untapped. Partner with Guardant Health to be on the cutting-edge of a new era that will ultimately lead to the development of more effective, targeted cancer therapies.

Learn about the Guardant Infinity platform

Add a new dimension of information to your view of cancer

The Human Genome Project revolutionized oncology research 20 years ago, and subsequent advances in next-generation sequencing-based liquid biopsy made tumor DNA more accessible. This enabled the development of many life-changing targeted therapies. However, genomics alone is a narrow view of cancer. Epigenetic alterations have been identified in numerous cancers1 and epigenomic information can provide critical insights into tumor heterogeneity2, disease progression3,4, and treatment response5. This additional dimension of insights enables more targeted and personalized treatment strategies.

Methylation sequencing dramatically improves sensitivity in cancer monitoring compared to genomic signals alone

Methylation sequencing features a lower limit of detection (LoD) and a signal independent from clonal hematopoiesis of indeterminate potential (CHIP) variants/biological noise6.

Illustration of late-stage circulating tumor fraction (TF)

With a lower LoD, methylation signal can identify and quantify tumor signal in early and late-stage cancers with as low as 0.001% circulating tumor fraction, enabling identification of tumor signal in 15-50% more cancer patients compared to genomic signal alone6.

Discover the next generation of biomarkers

Promoter methylation and unique methylation signatures can serve as novel epigenomic biomarkers for multiple precision oncology applications. Research has already shown that these next-generation biomarkers have the potential to:

Expand patient reach by capturing alterations not identified through genomic biomarkers11

Predict therapeutic response and overall survival12,13,14

Improve patient stratification by revealing more cancer subtypes and introducing additional biomarkers15,16

Access deeper insights with our innovative methylation technology

With the Guardant Infinity platform, you can access epigenomic insights for your translational research today. Epigenomic coverage allows for less sample input requirements and improves sensitivity over traditional bisulfite-based methods17.

Molecular recovery of Guardant Infinity methylation technology compared with bisulfite methods
Increase sensitivity in ctDNA detection with up to 1300% greater molecule recovery over conventional bisulfite-based methods17.

Start combining genomic
and epigenomic insights

Introducing GuardantINFINITY™— a comprehensive assay providing genomic and epigenomic profiling insights for biomarker discovery and development of cancer therapies today and beyond.

Learn more about GuardantINFINITY

Featured Posters

AACR 2023 Poster: A method for Quantifying circulating tumor DNA level and Molecular Response using Methylome Sequencing
AACR 2023 Poster: Analytical validation of a robust integrated genomic and epigenomic liquid biopsy for biomarker discovery, therapy selection, and response monitoring
AACR 2023 Poster: Use of circulating tumor DNA ( ctDNA ) for early assessment of treatment response in patients with non small cell lung cancer (NSCLC): A real world (RW) analysis incorporating baseline ctDNA level and molecular response
AACR 2023 Poster: Using Kmerizer, a germline and somatic genotyper for immune associated complex alleles in GuardantINFINITY, for immunotherapy response prediction using cfDNA
AACR 2023 Poster: BRCA1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy
AACR 2023 Poster: Validation of a bioinformatic model for classifying non-tumor variants in a cell-free DNA liquid biopsy assay
View all posters

Contact Us

Contact our biopharma team to see how we can help you accelerate precision oncology and bring the next generation of cancer therapies to patients sooner.

  1. Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. 2017 Jul 21;357(6348):eaal2380. doi: 10.1126/science.aal2380.
  2. Klughammer J, Kiesel B, Roetzer T, et al. The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nat Med 24, 1611–1624 (2018). https://doi.org/10.1038/s41591-018-0156-x
  3. Yoshimi A, Lin KT, Wiseman DH, et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature 574, 273–277 (2019). https://doi.org/10.1038/s41586-019-1618-0
  4. Teixeira VH, Pipinikas CP, Pennycuick A, et al. Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. Nat Med 25, 517–525 (2019). https://doi.org/10.1038/s41591-018-0323-0
  5. Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, et al. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respir Med. 2018 Oct;6(10):771-781. doi:10.1016/S2213-2600(18)30284-9
  6. Greenwald WW, He Y, Chen S, et al. (2022). Accurate epigenomic estimates of circulating tumor fraction in large-scale clinical data. Cancer Research, 82(12_Supplement), 3758-3758.
  7. Zhang W, Ma Y, Li Y, et al. Genomic landscapes of metastatic patterns in colorectal cancer. Cancer Discov. 2020;10(12):1780-1795.
  8. Zill OA, Banks KC, Fairclough SR, et al. The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Clin Cancer Res. 2017;23(15):4354-4361.
  9. Guardant data on file
  10. Guardant data on file
  11. Sahnane N, Carnevali I, Formenti G, et al. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor. Int J Mol Sci. 2020 Dec 19;21(24):9708. doi:10.3390/ijms21249708.
  12. Zhang Y, Wang F, Zhou Y, et al. PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance. Oncotarget. 2017 Sep 27;8(60):101535-101544. doi:10.18632/oncotarget.21803
  13. Janke F, Sultmann H, Becker M, et al. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients. Clin Epigenet. 2022;14(1):163.
  14. Elazezy M, Prieske K, Kluwe L, et al. BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer. Mol Oncol. 2021 Dec;15(12):3615-3625. doi: 10.1002/1878-0261.13108
  15. Berchuck JE, Prandi D, Schiewer MJ, et al. Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. Clin Cancer Res. 2022;28(5):928-938. doi:10.1158/1078-0432.CCR-21-1955
  16. Prajzendanc K, Marczuk J, Swoboda P, et al. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer. Int J Cancer. 2020 Mar 1;146(5):1293-1298. doi:10.1002/ijc.32489
  17. Guardant data on file